Ariad Pharmaceuticals (ARIA) 7.14 $ARIA
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?
at The Street - Fri Apr 11, 2:07PM CDT
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Ariad Pharmaceuticals Has Returned 101.6% Since SmarTrend Recommendation (ARIA)
Comtex SmarTrend(R) - Tue Apr 08, 9:07AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 5 months, Ariad Pharmaceuticals has returned 101.63% as of today's recent price of $7.40.
Mallinckrodt to Buy Drugmaker Questcor Pharmaceuticals for about $5.6B; Tesla Rated "Outperform" by RW Baird
ACCESSWIRE - Tue Apr 08, 12:00AM CDT
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) - For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA
3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 1:10PM CDT
Following its late 2012 approval by the Food and Drug Administration to treat two rare types of leukemia, Ariad Pharmaceuticals ' shareholders have experienced the full roller-coaster ride of unwavering success and unfathomable failure. ...
Apollo Education Sinks on Disappointing Earnings; Rubicon Project Makes Grand Debut on NYSE
ACCESSWIRE - Wed Apr 02, 11:12PM CDT
The Rubicon Project, Inc. (NYSE: RUBI) - For an in-depth report on the Rubicon Project, Inc. follow: www.BullTrends.com/stockquote/RUBI
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic?
Brian Nichols, The Motley Fool - Motley Fool - Wed Apr 02, 4:16PM CDT
Back in January, the Daily Mail ran a story suggesting that pharmaceutical companies Eli Lilly and GlaxoSmithKline had shown interest in Ariad Pharmaceuticals . According to another recent article by the same publication, however, Jazz...
Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz, Intercept, Community Health, and United Technologies
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Community Health Systems, Inc. (NYSE: CYH), and United Technologies Corporation (NYSE: UTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
Business Wire - Wed Apr 02, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD's chairman and chief executive officer, Harvey J. Berger, M.D.
4 Stocks Under $10 Moving Higher
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Technical Pointers on Top Gainers -- Research on ARIAD Pharma, Arotech, Restoration Hardware Holdings, and Sprouts Farmers Market
PR Newswire - Mon Mar 31, 11:52AM CDT
The US markets saw a positive sentiment on Friday, March 28, 2014, with the NASDAQ Composite closing at 4,155.76, up 0.11%, the Dow Jones Industrial Average ending the session at 16,323.06, up 0.36% and the S&P 500 edging 0.46% lower to finish the trading session at 1,857.62. During the session, Health Care and Telecommunication Services sectors ended in negative, while some positive momentums were observed in the Consumer Discretionary, Energy, and Industrials sectors. A number of stocks saw large movements, including ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Arotech Corp. (NASDAQ: ARTX), Restoration Hardware Holdings Inc. (NYSE: RH) and Sprouts Farmers Market Inc. (NASDAQ: SFM). Free technical research on ARIA, ARTX, RH and SFM can be downloaded upon signing up at:
Newmont Mining Corp Denies Cutting Output; Indonesian Copper and Gold Mine and Ford Raised CEO Alan Mulally's Compensation by 11%
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) - For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA
Most active Nasdaq-traded stocks
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).
Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM
at The Street - Wed Mar 26, 4:14PM CDT
Novartis' ceritinib is a next-generation ALK inhibitor already under FDA review as a new treatment for lung cancer.
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
PR Newswire - Tue Mar 25, 7:55AM CDT
Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
Business Wire - Mon Mar 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene.
The Next Big Biotech Mover: Ariad Pharma
at The Street - Wed Mar 19, 1:00PM CDT
Ariad Pharmaceuticals could be the next biotech stock setting up for a monster move higher, according to Roberto Pedone.
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?
at The Street - Fri Apr 11, 2:07PM CDT
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Ariad Pharmaceuticals Has Returned 101.6% Since SmarTrend Recommendation (ARIA)
Comtex SmarTrend(R) - Tue Apr 08, 9:07AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 5 months, Ariad Pharmaceuticals has returned 101.63% as of today's recent price of $7.40.
Mallinckrodt to Buy Drugmaker Questcor Pharmaceuticals for about $5.6B; Tesla Rated "Outperform" by RW Baird
ACCESSWIRE - Tue Apr 08, 12:00AM CDT
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) - For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA
3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 1:10PM CDT
Following its late 2012 approval by the Food and Drug Administration to treat two rare types of leukemia, Ariad Pharmaceuticals ' shareholders have experienced the full roller-coaster ride of unwavering success and unfathomable failure. ...
Apollo Education Sinks on Disappointing Earnings; Rubicon Project Makes Grand Debut on NYSE
ACCESSWIRE - Wed Apr 02, 11:12PM CDT
The Rubicon Project, Inc. (NYSE: RUBI) - For an in-depth report on the Rubicon Project, Inc. follow: www.BullTrends.com/stockquote/RUBI
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic?
Brian Nichols, The Motley Fool - Motley Fool - Wed Apr 02, 4:16PM CDT
Back in January, the Daily Mail ran a story suggesting that pharmaceutical companies Eli Lilly and GlaxoSmithKline had shown interest in Ariad Pharmaceuticals . According to another recent article by the same publication, however, Jazz...
Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz, Intercept, Community Health, and United Technologies
PR Newswire - Wed Apr 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Community Health Systems, Inc. (NYSE: CYH), and United Technologies Corporation (NYSE: UTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
Business Wire - Wed Apr 02, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD's chairman and chief executive officer, Harvey J. Berger, M.D.
4 Stocks Under $10 Moving Higher
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Technical Pointers on Top Gainers -- Research on ARIAD Pharma, Arotech, Restoration Hardware Holdings, and Sprouts Farmers Market
PR Newswire - Mon Mar 31, 11:52AM CDT
The US markets saw a positive sentiment on Friday, March 28, 2014, with the NASDAQ Composite closing at 4,155.76, up 0.11%, the Dow Jones Industrial Average ending the session at 16,323.06, up 0.36% and the S&P 500 edging 0.46% lower to finish the trading session at 1,857.62. During the session, Health Care and Telecommunication Services sectors ended in negative, while some positive momentums were observed in the Consumer Discretionary, Energy, and Industrials sectors. A number of stocks saw large movements, including ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Arotech Corp. (NASDAQ: ARTX), Restoration Hardware Holdings Inc. (NYSE: RH) and Sprouts Farmers Market Inc. (NASDAQ: SFM). Free technical research on ARIA, ARTX, RH and SFM can be downloaded upon signing up at:
Newmont Mining Corp Denies Cutting Output; Indonesian Copper and Gold Mine and Ford Raised CEO Alan Mulally's Compensation by 11%
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) - For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA
Most active Nasdaq-traded stocks
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).
Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM
at The Street - Wed Mar 26, 4:14PM CDT
Novartis' ceritinib is a next-generation ALK inhibitor already under FDA review as a new treatment for lung cancer.
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
PR Newswire - Tue Mar 25, 7:55AM CDT
Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
Business Wire - Mon Mar 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene.
The Next Big Biotech Mover: Ariad Pharma
at The Street - Wed Mar 19, 1:00PM CDT
Ariad Pharmaceuticals could be the next biotech stock setting up for a monster move higher, according to Roberto Pedone.
